Cann Pharmaceutical Ltd.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Cann Pharmaceutical Ltd. - overview
Established
2007
Location
Tel Aviv, -, Israel
Primary Industry
Biotechnology
About
Based in Tel Aviv, Israel, and founded in 2007, Cann Pharmaceutical Ltd. , dba Better is a global pharmaceutical company that specializes in cannabis-based pharmaceuticals. In February 2022, InterCure Ltd. acquired Cann Pharmaceutical Ltd.
for USD 35 million. As of 2022, Kobi Molcho is the CEO of the company. The company specializes in cannabis cultivation, marketing, commercialization, and research of medical cannabis products for a variety of medical indications. The firm provides marketing services for cannabis strains dedicated to conditions and indications such as epilepsy, autism, chronic pain, and cancer, and treats patients every month.
Better's products include inflorescence, oils, and CBD.
Current Investors
InterCure Ltd.
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Specialty Pharmaceuticals
Website
www.better-global.com
Verticals
Cannabis/Medical Marijuana, Manufacturing
Company Stage
Add-on
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.